A phase 2 study of DT-216
Latest Information Update: 07 Aug 2024
At a glance
- Drugs DT-216 (Primary)
- Indications Friedreich's ataxia
- Focus Therapeutic Use
Most Recent Events
- 05 Aug 2024 According to a Design Therapeutics media release, the company expects to start this study in 2025.
- 20 Mar 2023 New trial record
- 14 Mar 2023 According to a Design Therapeutics media release, the company expects to start this study in the second half of 2023.